| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
(R)-M3913 does not have a defined pharmacological target in the available literature. The parent compound M3913 is an antitumor compound with antiproliferative activity against cancer cells, but its specific molecular target has not been detailed in the available references. As an enantiomer, (R)-M3913 is used to investigate the stereochemical requirements for the biological activity of this compound class.
|
|---|---|
| ln Vitro |
(R)-M3913 is the (R)-enantiomer of M3913 and is not expected to exhibit the same level of antiproliferative activity as the active enantiomer. The parent compound M3913 has demonstrated antiproliferative activity against cancer cells, but the specific activity of the (R)-enantiomer has not been detailed in the available literature. (R)-M3913 is used as a negative control or to study the stereochemical requirements for activity.
|
| ln Vivo |
In vivo activity of (R)-M3913 has not been reported in the available literature. As an enantiomer of an antitumor compound, it may be used in preclinical studies to investigate the pharmacokinetic and pharmacodynamic differences between enantiomers. The parent compound M3913 is an antitumor compound with antiproliferative activity, but in vivo efficacy data for (R)-M3913 specifically have not been detailed.
|
| Enzyme Assay |
Non-cell-based binding assays for (R)-M3913 have not been detailed in the available literature. As an enantiomer of an antitumor compound, standard binding assays could include surface plasmon resonance or isothermal titration calorimetry to measure binding to the target protein, if the target is known. The compound may also be characterized in biochemical assays measuring inhibition of the target enzyme or pathway.
|
| Cell Assay |
Cellular assays for (R)-M3913 typically involve cancer cell lines to assess antiproliferative activity. A representative protocol includes: culturing cancer cells (e.g., breast, lung, or colon cancer cell lines) in appropriate medium, treating with (R)-M3913 at various concentrations (0.001–100 μM) for 48–72 hours, and assessing cell viability using MTT or CellTiter-Glo assays. The activity of (R)-M3913 is compared to that of the active enantiomer to determine the stereochemical requirements for antiproliferative activity.
|
| Animal Protocol |
In vivo animal studies with (R)-M3913 have not been reported in the available literature. If conducted, a typical protocol would involve xenograft mouse models of cancer, with administration of the compound via oral gavage or intraperitoneal injection at doses determined from pharmacokinetic studies. The antitumor efficacy of the (R)-enantiomer would be compared to that of the active enantiomer.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (R)-M3913 have not been detailed in the available literature. The compound has a molecular weight of 396.89 g/mol and is expected to have reasonable oral bioavailability. It is soluble in DMSO at ~100 mg/mL (~251.96 mM) and can be formulated for in vivo administration using 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline at ≥2.5 mg/mL. The compound is stored as a powder at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
As a research compound, (R)-M3913 is not intended for human therapeutic use, and comprehensive toxicological data are not available. Standard safety precautions should be followed when handling the compound, including the use of personal protective equipment and proper chemical hygiene practices. The compound is typically stored at -20°C in a sealed container, protected from moisture and light.
|
| References | |
| Additional Infomation |
(R)-M3913 (Compound C-155) is the (R)-enantiomer of M3913, an antitumor compound with antiproliferative activity against cancer cells. The compound is used as a research tool to study the stereochemical requirements for the biological activity of this compound class. (R)-M3913 is available in high purity (99.17%) for research applications and is suitable for both in vitro and in vivo studies.
|
| CAS # |
2379783-61-4
|
|---|---|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~251.96 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.30 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (6.30 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution; with ultrasonication. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
